Stocks to buy for long term: Nifty 50, the benchmark index of the Indian stock market, has seen significant selling pressure of late. Take a look: Natco Pharma | Previous close: ₹ 1,364.65 | Target price: ₹ 1,680 | Upside potential: 23% Natco specialises in manufacturing complex generic products with few competitors, especially for the US market. Industry in-line credit …
The domestic brokerage Nuvama Institutional Equities anticipates better results from the pharmaceutical companies in Q1FY24. Additionally, the brokerage claimed that gRevlimid boosts at Dr. Reddy's Laboratories Ltd, Zydus Lifesciences Ltd, Sun Pharmaceutical Industries Ltd, Cipla Ltd, and Natco Pharma will help to maintain US stability. Aurobindo Pharma: The brokerage anticipated in its analysis that new product launches and increased market …
Shares of Dr Reddy’s Laboratories slipped 7 per cent in early trade on May 11, a day after the company posted its Q4 results. The drugmaker’s net profit for the quarter jumped 10-fold to Rs 959.2 crore from Rs 87.5 crore in the same period last year but still lagged the Street’s estimate of Rs 1,093.6 crore. “Dr Reddys’ reported …
